Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

HSN2 Inhibitors

HSN2 inhibitors are chemical compounds that target and inhibit the function of HSN2, which stands for Hereditary Sensory Neuropathy type 2. HSN2 is a protein that plays a crucial role in the proper development and function of sensory neurons, and its inhibition can be achieved through compounds specifically designed to interfere with its activity. These inhibitors may have a diverse range of chemical structures, often designed to bind selectively to specific domains or active sites of the HSN2 protein. By interfering with the normal function of HSN2, these inhibitors can modulate the associated signaling pathways and processes regulated by the protein. This can be crucial for understanding the biological roles of HSN2, especially since it is linked to complex pathways involving neuronal growth, survival, and cellular communication.

Structurally, HSN2 inhibitors are varied but share a common mechanism of targeting the protein's functional domains, which can involve covalent or non-covalent interactions. The specificity of these inhibitors can be enhanced through modifications to their chemical backbones, functional groups, or steric properties, which ensures that they can effectively bind to HSN2 without significantly affecting other proteins or cellular components. Research into these inhibitors often focuses on their binding affinities, mechanisms of action, and how their structural variations influence their inhibitory capabilities. Additionally, studies on HSN2 inhibitors may involve investigations into their biophysical properties, such as solubility, stability, and molecular interactions within cellular environments, as these properties are critical to understanding their behavior and effects within biological systems. The design and study of HSN2 inhibitors offer insights into protein function regulation and serve as powerful tools for probing the role of HSN2 in cellular processes and sensory neuron function.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin may inhibit WNK1 expression by blocking PI3K signaling, which is involved in WNK1 transcriptional regulation.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin could inhibit WNK1 expression by interfering with mTOR signaling, which plays a role in WNK1 protein translation.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Staurosporine might inhibit WNK1 expression by inhibiting its kinase activity, leading to decreased WNK1 protein stability.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

PD98059 may inhibit WNK1 expression by blocking MAPK signaling, which is involved in the transcriptional regulation of WNK1.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 could inhibit WNK1 expression by blocking p38 MAPK signaling, which regulates WNK1 transcriptional activity.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 may inhibit WNK1 expression by blocking PI3K signaling, which regulates WNK1 transcription and protein stability.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 might inhibit WNK1 expression by blocking JNK signaling, which regulates WNK1 transcriptional activity.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126 could inhibit WNK1 expression by blocking MAPK signaling, which plays a role in the transcriptional regulation of WNK1.

SB 431542

301836-41-9sc-204265
sc-204265A
sc-204265B
1 mg
10 mg
25 mg
$80.00
$212.00
$408.00
48
(1)

SB431542 may inhibit WNK1 expression by blocking TGF-beta signaling, which regulates WNK1 transcriptional activity.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Bortezomib might inhibit WNK1 expression by blocking proteasomal degradation pathways involved in WNK1 protein turnover.